Innovation Observatory > Reports > Drugs > Enzalutamide (Xtandi) for non-metastatic prostate cancer

< Back

Enzalutamide (Xtandi) for non-metastatic prostate cancer


Cancer and Palliative Care

September 2017

Enzalutamide (Xtandi) is a drug which blocks the effect of the hormone testosterone on the prostate and so slows down the growth of the cancer. Enzalutamide is taken as four capsules once a day. If licenced in the UK, it could provide an additional treatment option for patients with non-metastatic prostate cancer

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory



Related Information

Load More Related Posts
Get Alerts